Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir

Clinical perspective on antiretroviral drug–drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine

(2010) Thomas N Kakuda et al.   ANTIVIRAL THERAPY

Lack of Interaction Between the HIV Integrase Inhibitor S/GSK1349572 and Tenofovir in Healthy Subjects

(2010) Ivy Song et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Etravirine–raltegravir, a marked interaction in HIV-1-infected patients: about four cases

(2009) Amélie Ménard et al.   AIDS

Integrase Inhibitors: A Novel Class of Antiretroviral Agents

(2009) Jason J Schafer et al.   ANNALS OF PHARMACOTHERAPY

Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers

(2009) S. Min et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects

(2008) M. S. Anderson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

(2008) Samantha Abel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY